• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jeffrey W. Clark, MD

Publications

  • Dahlberg SE, Shapiro GI, Clark JW, Johnson BE.Evaluation of statistical designs in phase I expansion cohorts: the dana-farber/harvard cancer center experience.Journal of the National Cancer Institute. 2014 Jul;106(7).
    24963024
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG.A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.Int J Radiat Oncol Biol Phys. 2014 May 24.
    24867540
  • Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Clin Cancer Res. 2014 Apr 1;20(7):1884-90.
    24478380
  • Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P.Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.J Natl Compr Canc Netw. 2014 Mar 1;12(3):323-6; quiz 326.
    24616538
  • Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.J Gastrointest Cancer. 2014 Mar;45(1):34-9.
    24006244
  • Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX.Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14.
    24121453
  • Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-Del Castillo C, Ryan DP, Hong TS.FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience.Oncologist. 2013 May 8.
    23657686
  • Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, Lorusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR.Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma.J Clin Oncol. 2013 Apr 22.
    23610116
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH.Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.J Clin Oncol. 2012 Aug 20;30(24):2963-8.
    22778320
  • Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX.A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.Oncologist. 2011;16(3):310-8.
    21349948
  • Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS.Tolerability of Combined Modality Therapy for Rectal Cancer in Elderly Patients Aged 75 Years and Older.Int J Radiat Oncol Biol Phys. 2011 Mar 4.
    21377289
  • Cusack JC, Clark JW, Curley SA, Sahani DV, Zukerberg LR.Case records of the Massachusetts General Hospital: Case 3-2011: a 58-year-old woman with a mass in the liver.N Engl J Med. 2011 Jan 27;364(4):362-70.
    21268729
  • Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.J Thorac Oncol. 2010 Dec;5(12):2044-6.
    21102269
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
    20979472
  • Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.Clin Cancer Res. 2010 Sep 15.
    20843836
  • Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK.A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer.Oncologist. 2010;15(8):845-51.
    20667969
  • Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8.
    20130879
  • Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK.Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.Oncologist. 2010;15(6):577-83.
    20484123
  • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.EMBO Mol Med. 2010 May;2(5):146-58.
    20432502
  • Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS.Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.Cancer. 2010 Apr 15;116(8):1879-86.
    20166212
  • Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.Lancet Oncol. 2010 Jan;11(1):48-54.
    19932054
  • Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK.Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.Cancer Res. 2009 Oct 15;69(20):7905-10.
    19826039
  • Willett CG,Duda DG,di Tomaso E,Boucher Y,Ancukiewicz M,Sahani DV,Lahdenranta J,Chung DC,Fischman AJ,Lauwers GY,Shellito P,Czito BG,Wong TZ,Paulson E,Poleski M,Vujaskovic Z,Bentley R,Chen HX,Clark JW,Jain RK.Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3020-6.
    19470921
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3027-35.
    19470923
  • Goulart BH,Clark JW,Lauwers GY,Ryan DP,Grenon N,Muzikansky A,Zhu AX.Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.J Hematol Oncol. 2009;2:13.
    19291303
  • Zhu AX,Clark JW.Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.Oncologist. 2009 Jan;14(1):67-9.
    19147690
  • Kulke MH,Hornick JL,Frauenhoffer C,Hooshmand S,Ryan DP,Enzinger PC,Meyerhardt JA,Clark JW,Stuart K,Fuchs CS,Redston MS.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.Clin Cancer Res. 2009 Jan 1;15(1):338-45.
    19118063
  • Zhu AX,Ready N,Clark JW,Safran H,Amato A,Salem N,Pace S,He X,Zvereva N,Lynch TJ,Ryan DP,Supko JG.Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.Clin Cancer Res. 2009 Jan 1;15(1):374-81.
    19118068
  • Wolpin BM,Hezel AF,Abrams T,Blaszkowsky LS,Meyerhardt JA,Chan JA,Enzinger PC,Allen B,Clark JW,Ryan DP,Fuchs CS.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.J Clin Oncol. 2009 Jan 10;27(2):193-8.
    19047305
  • Zuckerman DS, Clark JW.Systemic therapy for metastatic colorectal cancer: current questions.Cancer. 2008 May 1;112(9):1879-91.
    18338815
  • Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA.Trends in the use and role of biomarkers in phase I oncology trials.Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26. Review.
    18006773
  • Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92.
    17947726
  • Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK.Targeted therapy in rectal cancer.Oncology (Huntingt). 2007 Aug;21(9):1055-65; discussion 1065,. Review.
    17910311
  • Kwak EL, Clark JW, Chabner B.Targeted agents: the rules of combination.Clin Cancer Res. 2007 Sep 15;13(18):5232-7. Review.
    17875749
  • Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS.Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.Cancer Chemother Pharmacol. 2007 Oct;60(5):661-70.
    17216531
  • Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.Cancer. 2007 Aug 1;110(3):581-9.
    17583545
  • Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.Oncologist. 2007 Apr;12(4):426-37. Review.
    17470685
  • Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.Virchows Arch. 2007 May;450(5):529-537.
    17372756
  • Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.Cancer Chemother Pharmacol. 2007 Feb;59(3):285-93.
    16786333
  • Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC.A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.Cancer. 2006 Dec 1;107(11):2688-97.
    17075878
  • Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP.Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.Cancer. 2006 Nov 15;107(10):2482-9.
    17036355
  • Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS.Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.Clin Colorectal Cancer. 2006 Sep;6(3):208-13.
    17026790
  • Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 Jun;51(6):1033-8.
    16865563
  • Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS.A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.Cancer Invest. 2006 Apr-May;24(3):229-34.
    16809148
  • Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS.Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.Clin Colorectal Cancer. 2006 May;6(1):59-65.
    16796793
  • Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS.A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.Cancer Invest. 2006 Jun-Jul;24(4):346-50.
    16777685
  • Bendell JC, Lauwers GY, Willett C, Clark JW, Warshaw AL, Wain JC, Ryan DP.Pancreatoblastoma in a teenage patient.Clin Adv Hematol Oncol. 2006 Feb;4(2):150-3; discussion 154.
    16728924
  • Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.J Clin Oncol. 2006 Apr 20;24(12):1898-903.
    16622265
  • Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.J Clin Oncol. 2006 Apr 20;24(12):1892-7.
    16622264
  • McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS.The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.Am J Clin Oncol. 2006 Feb;29(1):40-4.
    16462501
  • Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B.Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?.Eur J Cancer. 2006 Mar;42(4):548-56.
    16426838
  • Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.J Clin Oncol. 2006 Jan 20;24(3):401-6.
    16421420
  • Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS.A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.Dig Dis Sci. 2005 Dec;50(12):2218-23.
    16416165
  • Jain RK, Duda DG, Clark JW, Loeffler JS.Lessons from phase III clinical trials on anti-VEGF therapy for cancer.Nat Clin Pract Oncol. 2006 Jan;3(1):24-40. Review.
    16407877
  • Eder JP, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2006 Jul;58(1):107-116.
    16362299
  • Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY.Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.J Clin Oncol. 2005 Nov 1;23(31):8136-9.
    16258121
  • Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS.Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.Clin Cancer Res. 2005 Sep 15;11(18):6650-6.
    16166444
  • Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.J Clin Oncol. 2005 Sep 1;23(25):6107-16.
    16135477
  • Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF.Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.Cancer. 2005 Oct 1;104(7):1418-27.
    16116597
  • Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ.Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.Clin Cancer Res. 2005 Aug 1;11(15):5472-80.
    16061863
  • Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.Oncologist. 2005 Jun-Jul;10(6):392-8.
    15967833
  • Tseng JF, Willett CG, Fernandez-del Castillo C, Ryan DP, Clark JW, Zhu AX, Rattner DW, Winkelmann JL, Warshaw AL.Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.Pancreatology. 2005;5(1):67-74.
    15775701
  • Willett CG, Del Castillo CF, Shih HA, Goldberg S, Biggs P, Clark JW, Lauwers G, Ryan DP, Zhu AX, Warshaw AL.Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.Ann Surg. 2005 Feb;241(2):295-9.
    15650640
  • McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS.Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.Am J Clin Oncol. 2004 Oct;27(5):485-8.
    15596916
  • Roberts TG, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW.Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.JAMA. 2004 Nov 3;292(17):2130-40.
    15523074
  • Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS.A phase II study of docetaxel in patients with metastatic carcinoid tumors.Cancer Invest. 2004;22(3):353-9.
    15493355
  • Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS.A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.Cancer. 2004 Sep 1;101(5):934-9.
    15329900
  • Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW.Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.Clin Cancer Res. 2004 Apr 1;10(7):2222-30.
    15073096
  • Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG.Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.Clin Colorectal Cancer. 2004 Feb;3(4):225-34.
    15025795
  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med. 2004 Feb;10(2):145-7.
    14745444
  • Eder JP, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P.A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-Fluorouracil in patients with advanced solid malignancies.Invest New Drugs. 2004 Apr;22(2):139-50.
    14739662
  • Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.Clin Cancer Res. 2003 Nov 1;9(14):5178-86.
    14613997
  • Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ.A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.Cancer Invest. 2003;21(4):505-11.
    14533439
  • Brugarolas J, Clark JW, Chabner B.Using "rationally designed drugs" rationally.Lancet. 2003 May 24;361(9371):1758-9.
    12781531
  • Michaelson MD, Ryan DP, Fuchs CS, Supko JG, Garcia-Carbonero R, Paul Eder J, Clark JW.A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.Cancer. 2003 Jan 1;97(1):148-54.
    12491516
  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW.Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.J Clin Oncol. 2002 Sep 15;20(18):3772-84.
    12228197
  • Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE.A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.Cancer. 2002 Jun 15;94(12):3186-91.
    12115351
  • Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG.Phase II study of paclitaxel and carboplatin for malignant melanoma.Am J Clin Oncol. 2002 Jun;25(3):283-6.
    12040289
  • Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J,.Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.Med Oncol. 2001;18(3):197-207.
    11917944
  • Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.Clin Cancer Res. 2002 Mar;8(3):691-7.
    11895897
  • Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW.A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.Cancer. 2002 Jan 1;94(1):97-103.
    11815964
  • Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN.Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.
    11761451
  • Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC.Quality of informed consent in cancer clinical trials: a cross-sectional survey.Lancet. 2001 Nov 24;358(9295):1772-7.
    11734235
  • McMahon PM, Halpern EF, Fernandez-del Castillo C, Clark JW, Gazelle GS.Pancreatic cancer: cost-effectiveness of imaging technologies for assessing resectability.Radiology. 2001 Oct;221(1):93-106.
    11568326
  • Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Clin Cancer Res. 2001 Feb;7(2):231-42.
    11234874
  • Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC.Quality of informed consent: a new measure of understanding among research subjects.J Natl Cancer Inst. 2001 Jan 17;93(2):139-47.
    11208884
  • Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP.A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.Cancer Chemother Pharmacol. 2000;46(4):319-28.
    11052630
  • Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW.A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.Cancer. 2000 Jan 1;88(1):180-5.
    10618622
  • Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS.Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer?.Cancer J Sci Am. 1999 Jul-Aug;5(4):242-7.
    10439171
  • Clark JW.Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-19-S18-24.
    9420017